~~<i id='81A34BD024'><strike id='81A34BD024'><tt id='81A34BD024'><pre id='81A34BD024'></pre></tt></strike></i>~~

Home» explore» knowledge

knowledge

author：fashion 2025-10-02 00:22:53 Page View：16935

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA early review: GLP
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

knowledge

Wildfire smoke exposes gaps in outdoor worker protections

ApersonwaitingforthesubwaywearsafilteredmaskassmokyhazefromwildfiresinCanadablanketsaneighborhoodinN

ASCO eve: Let’s set the table for this year's meeting

ThisistheonlineeditionofAdam’sBiotechScorecard,asubscriber-onlynewsletter.STAT+subscriberscansignuph

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

STAT Virtual Event: JPM Recap, Live!

Editor’snote:Alivestreamoftheeventwillbeembeddedbelowat1p.m.ET.Relivethisyear’sJ.P.MorganHealthcareC